Fuse Oncology has announced the expansion of FuseRx, its clinical workflow platform for radiation oncology, to include physicist, dosimetrist, therapist, and nurse roles.
This builds on the platform's July launch for physicians. The expanded workflow incorporates BluePrint, a treatment-planning application developed at the University of Michigan Department of Radiation Oncology and licensed to Fuse through U-M Innovation Partnerships.
FuseRx is designed to streamline the workflow from consult note and treatment intent through simulation, treatment planning, and scheduling within a single platform that connects to existing oncology information systems including Mosaiq and Aria.
The platform grew out of Cone Health Radiation Oncology, part of Risant Health, which has run the prototype FuseRx is built on for several years, according to Fuse. In that time, the department has reduced the time from consult to treatment to 3.4 days and seen 35% more patients than the U.S. average with 34% fewer full-time equivalents, the company said.
Fuse will demonstrate FuseRx at the American Society of Radiation Oncology (ASTRO) 2026 Annual Meeting, September 26to 30 in Boston.
